Cortexyme Inc. Stock News

Citigroup Inc. increased its position in Cortexyme, Inc. (NASDAQ:CRTX) by 50.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commiss

Insider buying decreased significantly last week. Notable Insider Buys: Accelerate Diagnostics, Inc., Keurig Dr Pepper Inc., Vishay Precision Group, Inc., Corte

Allogene Therapeutics, Personalis, Cortexyme, and La Jolla Pharmaceutical have all seen large stock purchases by insiders and big investors this month.

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investmen

Alzheimer's disease remains an unbreakable wall for biotech companies for decades. The recent fails in beta-amyloid thesis create an opportunity for better unde

Cortexyme, Inc. (NASDAQ:CRTX) Director David Lamond acquired 49,125 shares of Cortexyme stock in a transaction that occurred on Thursday, June 4th. The stock was acquired at an average cost of $41.73

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s and other degenerati

Upgrades * For Eaton Vance Corp (NYSE: EV), B of A Securities upgraded the stock from Neutral to Buy. In the second quarter, Eaton Vance showed an EPS of $0.80, compared to $0.89 from the year-ago q

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company

Insider buying decreased significantly last week. Notable Insider Buys: Mercury General Corporation, Cortexyme, Inc., New Mountain Finance Corporation, Berkshir

It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced financial results for th

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative di

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it